Trial · NCT07460362
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT07460362, Phase 2, Recruiting, Peking University Third Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma. Trials, record NCT07460362. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07460362
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
- NCT number
- NCT07460362
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 43 participants, estimated
- Lead sponsor
- Peking University Third Hospital
- Conditions
- MCL, Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- Interventions
- Glofitamab, Lenalidomide
- First posted
- 2026-03-10
- Last updated
- 2026-03-10
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | to evaluate the efficacy of glofitamab combined with lenalidomide in high-risk patients with R/R MCL by best overall response rate (BOR) at the end of induction. | 24 months | to evaluate the efficacy of glofitamab combined with lenalidomide in high-risk patients with R/R MCL by best overall response rate (BOR) at the end of induction, defined as the percent of patients who achieve a best complete response (CR) or partial response (PR) according to the 2014 Lugano response criteria for non-Hodgkin lymphoma at the end of induction. |
| Secondary | Objective Response Rate (ORR) | up to 24 months | ORR, defined as the proportion of patients with overall response rate at C6 and the end of induction, as determined by the investigator using 2014 Lugano Response Criteria. |
| Secondary | complete response rate (CRR) | Up to 24 months | CRR, defined as the proportion of patients with complete response rate（CRR）at C6 and the end of induction, and a best overall response of CR at any time during the studas determined by the investigator using 2014 Lugano Response Criteria. |
| Secondary | Duration of Response (DoR) | Up to 48 months | DoR, defined as the time from the first occurrence of a documented objective response (PR or CR) to disease progression or death from any cause (whichever occurs first) according to the 2014 Lugano Response Criteria, as determined by the investigator. |
| Secondary | Duration of Complete Response (DoCR) | Up to 48 months | DoCR, defined as the time from the initial occurrence of a documented CR until documented disease progression or death due to any cause, whichever occurs first according to the 2014 Lugano Response Criteria, as determined by the investigator. |
| Secondary | Progression-Free Survival (PFS) | Up to 48 months | PFS, defined as the time from the first study treatment to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator using 2014 Lugano Response Criteria. |
| Secondary | Overall Survival (OS) | Up to 48 months | OS, defined as the time from the first study treatment to the date of death from any cause. |
| Other | To evaluate the safety profiles of Glofitamab combined with lenalidomide in the treatment of high-risk mantle cell lymphoma | 48 months | List the number and frequency of hematological and non-hematological toxicity (NCI CTCAE v5.0) and calculate the incidence rate. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07460362
GET https://conductscience.org/api/trials/v1/NCT07460362/registered